Clinical and pharmacologic study of tributyrin: An oral butyrate prodrug

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 5, 2003, Pages 439-444

  Edelman, Martin J ^a,b   Bauer, Kenneth ^a   Khanwani, Shyam ^a,b   Tait, Nancy ^a   Trepel, Jane ^d   Karp, Judith ^a   Nemieboka, Noble ^c   Chung, Eun Joo ^d   Van Echo, David ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Butyrate; Differentiating agent; Histone deacetylase inhibitor

Indexed keywords

BUTYRIC ACID; NSC 661583; PRODRUG; TRIBUTYRIN;

ABDOMINAL CRAMP; ADULT; AGED; ANEMIA; ANOREXIA; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIFFERENTIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; LEG CRAMP; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

EID: 0038018593     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0580-5     Document Type: Article

References (18)

1. Prasad K (1980) Butyric acid: a small fatty acid with diverse biologic functions. Life Sci 27:1351-1358
2. Pellizzaro C, Coradini D, Daniotti A, Abolafio G, Daidone MG (2001) Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. Int J Cancer 91:654-657
3. Davis T, Kennedy C, Chiew YE, Clarke CL, deFazio A (2000) Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res 6:4334-4342
4. Wang QM, Feinman R, Kashanchi F, Houghton JM, Studzinski GP, Harrison LE (2000) Changes in E2F binding after phenylbutyrate-induced differentiation of Caco-2 colon cancer cells. Clin Cancer Res 6:2951-2958
5. Giermasz A, Nowis D, Jalili A, et al (2001) Antitumor activity of tributyrin in murine melanoma model. Cancer Lett 64:143-148
6. Maier, Reich E, Martin R, et al (2000) Tributyrin induces differentiation, growth arrest and apoptosis in androgen sensitive and androgen-resistant human prostate cancer cell lines. Int J Cancer 88:245-251
7. Conley BA, Egorin MJ, Tait N, et al (1998) Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clinical Cancer Res 4:629-634
8. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
9. Warrell RP, He L-Z, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621-1625
10. Newmark HL, Lupton JR, Young CW (1994) Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett 78:1-5
11. Chen Z-X, Breitman T (1994) Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res 54:3494-3499
12. Perrine SP, Ginger GD, Faller DV, et al (1993) A short term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 328:81-86
13. Carducci M, Bowling MK, Eisenberger M, et al. (1987) Phenylbutyrate (PB) for refractory solid tumors: phase I clinical and pharmacologic evaluation of intravenous and oral PB. Anticancer Res 17:3972-3973
14. Parodi PW (1997) Cows' milk fat components as potential anticarcinogenic agents. J Nutr 127:1055-1060
15. Marks PA, Richon VM, Rifkind RA (2001) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216
16. Witt O, Schmejkal S, Pekrun A (2000) Tributyrin plus all-transretinoic acid efficiently induces fetal hemoglobin expression in human erythroleukemia cells. Am J Hematol 64:319-321
17. Schroder CP, Maurer HR (2001) Tributyrin enhances the cytotoxic activity of interleukin2/interleukin 12-stimulated human natural killer cells against LS 174T colon cancer cells in vitro. Cancer Immunol Immunother 50:69-76
18. Siu LL, Von Hoff DD, Rephaeli A, et al (1998) Activity of pivaoyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony forming units. Invest New Drugs 16:113-119